Answers are grounded in this paper and cite their sources.
Retrospective study shows DS-8201 enhances efficacy in advanced HER2-positive breast cancer, indicating a promising treatment option.
DS-8201 showed significantly better efficacy and similar overall safety compared to TPC in patients with T-DM1-pretreated HER2-positive advanced breast cancer, supporting its use as a treatment option in this setting.
No takes yet. Share an insight, caveat, or question.
Wei Wu (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: